Statistical Analysis
intracranial bleeding, diabetes, death, ischemic stroke
INTRACRANIAL BLEEDING, MINOR, ISCHEMIC STROKE, DYSLIPIDEMIA, REGRESSION, HYPERTENSION, INTRACRANIAL BLEED, DIABETES
For this analysis, version 3 of the ASPREE data set (released December 2019) was used. This contains more extensive data fields and minor corrections to data in the original version used previously.Descriptive statistics are presented as frequency and percentage. Cox proportional hazards regression models were used in intention-to-treat analyses to evaluate the effect of aspirin on time to the first ischemic stroke, intracranial bleeding, and intracranial bleeding subtypes.Cause-specific hazards and cumulative incidence estimates were calculated to account for competing risks (eg, all-cause death and outcomes of the same type when analyzing subtypes for an outcome of interest). With ischemic stroke and first intracranial bleed, we assessed the consistency of treatment effect across several subgroups, including age (65-74, 75-84, and ≥85 years), sex (male and female), smoking status (current and former or never), diabetes, hypertension, dyslipidemia, frailty category, and country (Australia and US). Number needed to treat was calculated based on the restricted mean survival time among individuals assigned to aspirin or placebo.